Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sophia GeneticsSOPH -1.55%66 Earnings per Share (Diluted) is $-1.15 as of Jun. 2026. GuruFocus rates SOPH with a GF Score™ of 66/100 and a GF Value™ of $5.13 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 503 Healthcare Providers & Services companies, Sophia Genetics ranks worse than 58.85% on this metric.
Sophia Genetics's EPS (Basic) for the
three
months ended in Jun. 2026 was $-0.30.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was $-1.15.
During the past 3 years, the average EPS without NRIGrowth Rate was 5.90% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -2.80% per year.
During the past 8 years, Sophia Genetics's highest 3-Year average EPS without NRI Growth Rate was 8.80% per year. The lowest was -24.70% per year. And the median was -4.20% per year.
Sophia Genetics (NAS:SOPH) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Sophia Genetics Earnings per Share (Diluted) Related Terms
Sophia Genetics Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Sophia Genetics's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sophia Genetics Earnings per Share (Diluted) Chart
SOPH vs CTEV, PHR, WEAV: Earnings per Share (Diluted) Comparison
For the Health Information Services subindustry, Sophia Genetics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sophia Genetics PE Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sophia Genetics's PE Ratio distribution charts can be found below:
* The bar in red indicates where Sophia Genetics's PE Ratio falls into.
Sophia Genetics Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Sophia Genetics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.15
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-1.15 mean?
Sophia Genetics (SOPH) has a Earnings per Share (Diluted) of $-1.15 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Sophia Genetics and its competitors. According to the industry distribution chart, Sophia Genetics ranks #296 out of 503 companies in the Healthcare Providers & Services industry, placing it in the top 58.8%.
Is Sophia Genetics' Earnings per Share (Diluted) too high?
Sophia Genetics' current Earnings per Share (Diluted) is $-1.15. Based on the distribution chart, Sophia Genetics ranks #296 out of 503 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Sophia Genetics has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sophia Genetics' Earnings per Share (Diluted) compare to CTEV and PHR?
According to the Healthcare Providers & Services industry distribution chart, Sophia Genetics ranks #296 out of 503 companies for Earnings per Share (Diluted). This places Sophia Genetics in the lower half of its industry. The industry median Earnings per Share (Diluted) is 11.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Healthcare Providers & Services company?
The median Earnings per Share (Diluted) among Healthcare Providers & Services companies is 11.00, based on 503 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Sophia Genetics and its competitors. For the Healthcare Providers & Services industry, the median Earnings per Share (Diluted) is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sophia Genetics's current Earnings per Share (Diluted) is $-1.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sophia Genetics stock overvalued right now?
Based on GuruFocus' analysis, Sophia Genetics (SOPH) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.13, compared to a current price of $8.28 — trading 61.4% above its estimated fair value. The current Earnings per Share (Diluted) is $-1.15. Sophia Genetics' overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Sophia Genetics (SOPH), the current Earnings per Share (Diluted) is $-1.15 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sophia Genetics (SOPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sophia Genetics stock appears to be overvalued.
The current stock price of $8.28 is trading 61.4% above its estimated GF Value™ of $5.13.
GuruFocus considers Sophia Genetics to be Significantly Overvalued.
Key valuation signals for SOPH:
Earnings per Share (Diluted): $-1.15
GF Value™: $5.13 vs. price of $8.28 (61.4% above fair value)
No single metric tells the full story. See the SOPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
66GF Score
Get the complete analysis for SOPH
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SOPH has been successfully added to your 
